Journal Information
Share
Share
Download PDF
More article options
Visits
445
Scientific Letter
Full text access
Available online 3 March 2024
Analysis of the Evolution of Tuberculosis in Men and Women in Spain Between 2017 and 2022. Is There a Different Incidence Decline by Gender?
Visits
445
Teresa Rodrigoa,b,c,
Corresponding author
pii_tb_teresa_rodrigo@separ.es

Corresponding author.
, Eva M.a Taberneroa,d, Luis Anibarroa,e, José A. Gullóna,f, Juan F. Medinaa,g, Joan P. Milleta,h, Marta M.a García-Clementea,i, Antonia Sáeza,j, Joan A. Caylàb, José M.a García-Garcíaa, Integrated Tuberculosis, Non-Tuberculous Mycobacteria Research Programme Working Group PII-TBMNT of SEPAR 1
a Programa Integrado de Investigación en Tuberculosis y Micobacterias no Tuberculosas (PII-TB&MNT) de SEPAR, Barcelona, Spain
b Unidad de Investigación en Tuberculosis de Barcelona (fUITB), Barcelona, Spain
c Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
d Hospital Universitario de Cruces, Bilbao, Spain
e Complejo Hospitalario de Pontevedra, Pontevedra, Spain
f Hospital San Agustín, Avilés, Spain
g Hospital Universitario Virgen del Rocío, Sevilla, Spain
h Serveis Clinics de Barcelona, Barcelona, Spain
i Hospital Central de Asturias, Oviedo, Spain
j Axioma Comunicaciones, Sevilla, Spain
Ver más
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (1)
Table 1. Sociodemographic, Epidemiological, Clinical, Diagnostic and Treatment Characteristics and Risk Factors by Gender.
Full Text
To the Director,

Historically, the epidemiological burden of tuberculosis (TB) has been larger in men than in women and, in many societies, exposure to infectious cases differs between both sexes.1 Every year, more cases of TB are documented in men than in women worldwide,2 and prevailing surveys show this disparity.3

The study's goals were: to identify the characteristics and risk factors associated with gender and tuberculosis (TB), assess the linear trend of the incidence of cases by over time, and determine whether there are differences in diagnostic delay and treatment compliance.

All TB cases included in the Integrated Programme of Research in Tuberculosis and Non-Tuberculosis Mycobacteria (PII-TB&MNT) of SEPAR between 2017 and 2022 were included in a cross-central multicenter study. The χ2 test was used to analyze the gender differences, considering that they were statistically significant if p-value <0,05. A binary logistic regression was used and odds ratios (OR) and 95% confidence intervals (CI) were computed. The temporal trend of the variable was obtained using the χ2 linear trend test. IBM SPSS Statistics 22 statistical software was used to conduct the analysis.

The processing of personal data was in accordance with Spanish Organic Law 3/2018, of 5 December, on the Protection of Personal Data and the Guarantee of Digital Rights and the European Data Privacy Directive.

A sample of 1769 cases included in the registration between 2017 and 2020 was studied, of which 1220 (69%) were men and 549 women (31%). Multivariate analysis showed significant gender differences associated with men in the following categories: aged >60; in confinement; living alone or in groups; homeless; consume tobacco or alcohol. However, extrapulmonary localization was more common in women. There were no differences in the rates of diagnostic delay. There were no differences in the rates of diagnostic delay. There were differences in treatment compliance and treatment outcome, but these were not statistically significant (Table 1). There were also no significant differences in the pre-Covid and post-Covid periods in the ratio of men and women (p=0.59).

Table 1.

Sociodemographic, Epidemiological, Clinical, Diagnostic and Treatment Characteristics and Risk Factors by Gender.

  TotalN=1769 (100%)MenN=1220 (69%)WomenN=549 (31%)Univariate analysisMultivariate analysis
  N  N  N  OR (95% CI)  p-Value  OR (95% CI)  p-value 
Age (years)
≤45  910  51.4  581  47.6  329  59.9    Ref.    Ref. 
46–60  445  25.2  338  27.7  107  19.5  0.559 (0.433–0.722)  <0.001    0.154 
>60  414  23.4  301  24.7  113  20.6  0.663 (0.514–0.856)  0.002  0.488 (0.349–0.681)  <0.001 
Native country
Natives  1056  59.7  737  60.4  319  58.1    Ref.     
Immigrant  713  40.3  483  39.6  230  41.9    0.361     
Living situation
Confinement  37  2.1  30  2.5  1.3  0.391 (0.171–0.898)  0.027  0.340 (0.130–0.888)  0.028 
Family  1301  73.5  815  66.8  486  88.5    Ref.    Ref. 
Group  202  11.4  177  14.5  25  4.6  0.237 (0.154–0.365)  <0.001  0.153 (0.092–0.254)  <0.001 
Homeless  60  3.4  57  4.7  0.5  0.088 (0.027–0.283)  <0.001  0.249 (0.074–0.834)  0.024 
Alone  168  9.5  140  11.5  28  5.1  0.335 (0.220–0.511)  <0.001  0.288 (0.166–0.498)  <0.001 
Unknown  0.1  0.1    –    – 
Smoking
Ex-smokers +6 months  238  13.5  198  16.2  40  7.3  0.223 (0.154–0.321)  <0.001  0.248 (0.158–0.389)  <0.001 
Smokers  707  40.0  590  48.4  117  21.3  0.219 (0.172–0.278)  <0.001  0.349 (0.259–0.471)  <0.001 
No smokers  824  46.6  432  35.4  392  71.4    Ref.    Ref. 
Alcoholism
No  1259  71.2  764  62.6  495  90.2    Ref.    Ref. 
Yes  476  26.9  426  34.9  50  9.1  0.181 (0.132–0.248)  <0.001  0.304 (0.208–0.445)  <0.001 
Unknown  34  1.9  30  2.5  0.7  0.206 (0.072–0.588)  0.003    0.287 
Drug use
No  1609  91.0  1080  88.5  529  96.4    Ref.    Ref. 
Yes  160  9.0  140  11.5  20  3.6  0.292 (0.180–0.471)  <0.001    0.939 
HIV infection
No  1585  89.6  1090  89.3  495  90.2    Ref.    Ref. 
Yes  52  2.9  43  3.5  1.6  0.461 (0.223–0.953)  0.037    0.822 
Unknown  132  7.5  87  7.1  45  8.2    0.497    0.355 
Immunosuppression
No  1502  84.9  1033  84.7  469  85.4    Ref.     
Yes  184  10.4  129  10.6  55  10.0    0.712     
Unknown  83  4.7  58  4.8  25  4.6    0.833     
Previous treatment
No  1652  93.4  1133  92.9  519  94.5    Ref.    Ref. 
Yes  117  6.6  87  7.1  30  5.5    0.193    0.762 
Localization of tuberculosis
Pulmonary  1382  78.1  1003  82.2  379  69.0  0.482 (0.382–0.609)  <0.001    0.296 
Pleural  241  13.6  166  13.6  75  13.7    0.975     
Disseminated  125  7.1  83  6.8  42  7.7    0.520     
Extrapulmonary only  185  10.5  90  7.4  95  17.3  2.627 (1.930–3.576)  <0.001  2.075 (1.395–3.084)  <0.001 
Diagnostic delay (days)
Median; IQR  62  30–120  61  30–115  64  31–134    0.075    0.623 
Medical judgement                     
Compliant patient  1558  88.1  1059  86.8  499  90.9    Ref.    Ref. 
Non-compliant patient  78  4.4  67  5.5  11  2.0  0.348 (0.183–0.665)  0.001    0.123 
Unknown  133  7.5  94  7.7  39  7.1    0.521    0.562 
Treatment outcome
Cured  634  35.8  467  38.3  167  30.4    Ref.    Ref. 
Completed treatment  565  31.9  344  28.2  221  40.3  1.797 (1.407–2.294)  <0.001    0.523 
Prolonged treatment  364  20.6  252  20.7  112  20.4    0.134    0.136 
Default  0.1  0.2    –    – 
Lost to follow-up  32  1.8  28  2.3  0.7    0.091    0.191 
Covid periods
Pre-Covid  1264  71.5  867  71.1  397  72.3    Ref.     
Post-Covid  505  28.5  353  28.9  152  27.7    0.591     

Values in bold: p-value < 0,05

IQR: interquartile range.

The annual incidence of cases has decreased significantly (y=141006.98x), although the linear trend shows that it is decreasing in women (y=13300.66x) while being positive in men (y=118+0.06x) (Fig. 1).

Fig. 1.

Linear trend in the evolution of the incidence of cases in women and men (2017–2022).

(0.08MB).

There have not been many studies on the relationship between gender and tuberculosis in Spain; nonetheless, certain data from national and autonomous TB control projects are accessible4–6 showing numbers between 39.6% and 40% of women and between 60% and 60.4% of men between 2015 and 2017. However, they do not study the factors to which they may be related.

The SEPAR PII-TB&MNT evaluation, conducted between 2006 and 2016, showed that the population studied had a significant declining trend in the number of cases in women. The percentage of cases among women in the last two years of the evaluation (2015–2016),7 was also lower than the figure reported in the World Health Organization's Global Tuberculosis Report 2019 (30.8% and 25.4% vs 32%),8 and the figures in our current study are also lower than those in the World Health Organization's Global Tuberculosis Report 2023 (31% vs 33%).9

A constraint of this research is that, apart from the variables examined here, we also need to consider other studies that have identified additional characteristics related to gender. One of them at University College London10 compared a short 4-month treatment to the 6-month standard and found gender differences in treatment outcomes without any objective biological causes. Others conclude that there is an urgent need for a greater understanding of gender-related barriers.11 Another study found evidence that, in low- and middle-income countries, men are more at risk and have less access to screening and diagnostic services.12 Some speculate that the development of tuberculosis may include a variety of physiopathological processes13 and according to some authors, biological factors, such as sex hormones and genetic factors, could contribute to the host's immunity during tuberculosis.14

Despite the decline in the inclusion of cases during the Covid pandemic15 (overload of medical services, possible reduction of cases due to the wearing of facemasks, decreased contact in public places or delayed diagnosis) and weakened TB control systems,16,17 it can be concluded that there are significant gender differences in the incidence, age, living situation, tobacco and alcohol consumption and the localization of tuberculosis patients and that the trend in the number of cases in women continues to decrease.

Ethical Approval

The Biomedical Research Ethics Committees of the different participating centres approved this study.

Authors’ Contributions

Teresa Rodrigo: conception and design of the study; acquisition, analysis and interpretation of data, and writing of the article.

Eva M. Tabernero, Luis Anibarro, José A. Gullón, Juan F Medina, Joan P. Millet, Marta M. García-Clemente, Joan A Caylà, José M. García-García: critical review of the intellectual content, final approval of the version presented.

Antonia Sáez: methodology design and statistical analysis of data. Working Group of the Integrated Tuberculosis and NMT Research Program (PII-TB & NMT): collection and contribution of data.

Funding

Grant from the Spanish Society of Pulmonology and Thoracic Surgery (880/2019).

Conflicts of Interest

The authors declare no conflicts of interest.

Appendix A
Integrated Tuberculosis Research Programme Working Group

Abigail Macías Paredes (Hospital Comarcal Sant Jaume de Calella); Adrián Sánchez Montalvá (Hospitales Vall d’Hebrón); Álvaro Cecilio Irazola (Hospital Universitario Lozano Blesa); Ángel Domínguez Castellanos (Hospital Universitario Virgen Macarena); Antón Penas Truque (Hospital Universitario Lucus Augusti); Antoni Soriano Arandes (Hospitales Vall d’Hebrón); Belén Mª Navas Bueno(Hospital General Básico Santa Ana); Dunibel Morillo (Hospital Ernest Lluch; Martín Elvira Pérez Escolano (Hospital del SAS de Jerez); Estefanía Sánchez Martínez (Parc Sanitari Sant Joan de Deu de Sant Boi); Francisco Sanz Herrero (Hospital General Universitario de Valencia); Guillermo J Pérez (Hospital Universitario de Gran Canaria “Dr. Negrín”), Igor Iturbe Susilla (Hospital Universitario de Basurto); Isabel López Aranaga (Hospital Universitario de Basurto); Isabel Santamaría Mas (Hospital de Txagorritxu); Isabel Suárez Toste (Hospital Universitario de Canarias); Israel Molina Pinagorte (Serveis Clinics de Barcelona); Javier Garros Garay (Hospital Santa Marina); Jonathan Cámara Fernández (Parc Sanitari Sant Joan de Deu); José Antonio Caminero Luna (Hospital Universitario de Gran Canaria “Dr. Negrín”); José David Cardoso Landivar (Hospital Universitario Vall d’Hebrón); José Luis Vidal Pérez (Complejo Hospitalario La Paz-Cantoblanco-Carlos III); Josefina Sabria Mestras (Hospital de Sant Joan Despí Moisès Broggi); Juan Diego Álvarez Mavárez (Hospital Carmen y Severo Ochoa); Juan Rodríguez López (Hospital San Agustín); Lander Altube Urrengoetxea (Hospital de Galdakao); Lydia Luque Chacón (Hospital de Sant Joan Despí Moisès Broggi); Mª Ángeles Jiménez Fuentes (Unitat de Tuberculosi Vall d’Hebrón-Drassanes); Mª Jesús Ruiz Serrano (Hospital General Universitario Gregorio Marañón); Mª Luisa de Souza Galvao (Unitat de Tuberculosi Vall d’Hebrón-Drassanes); Magnolia Nieto Marcos (Hospital Dr Moliner); María Somoza González (Consorcio Sanitario de Tarrasa); Marina Lumbierres Burgués (Serveis Clinics de Lérida); Miguel Santín Cerezales (Hospital Universitario de Bellvitge); Miguel Zabaleta Murgiondo (Hospital Universitario de Valdecilla); Neus Altet Gómez (Serveis Clinics de Barcelona); Pablo Fernández Álvarez (Hospital Álvarez-Buylla); Paloma Gijón Vidaurreta (Hospital General Universitario Gregorio Marañón); Rocío Martínez Gutiérrez (Hospital San Agustín de Avilés); Sarai Quirós Fernández (Hospital de Basurto); Silvia Dorronsoro Quintana (Hospital de Zumárraga); Vanesa Deya Vadel l (Hospital Son Llatzer); Virginia Pomar Solchaga (Hospital Universitario de la Santa Creu y Sant Pau); Xavier Casas García (Serveis Clinics de Barcelona); Yoel González Díaz (Serveis Clinics de Barcelona).

References
[1]
V. Farga, J.A. Caminero.
Tuberculosis, 3ra edición.
Rev Med Chile, 139 (2011), pp. 681-682
[2]
World Health Organization (WHO). Case notifications. Available from: http://www.who.int/tb/country/data/download/en/.
[3]
World Health Organization (WHO).
Global tuberculosis report 2017.
World Health Organization, (2017),
[4]
Agencia de Salud Pública de Barcelona, Programa de Prevención y Control de Tuberculosis de Barcelona.
La Tuberculosis en Barcelona. Informe 2016. Barcelona.
(2018),
[5]
Dirección Xeral de Saúde Pública.
Informe da tuberculose en Galicia. Características dos casos de tuberculose de Galicia no ano 2017. Evolución do período 1996-2017 [monografía en internet].
Xunta de Galicia, Consellería de Sanidade, (2019),
[6]
R. Cano-Portero, R. Amillategui-dos Santos, R. Boix-Martínez, A. Larrauri-Cámara.
Epidemiología de la tuberculosis en España. Resultados obtenidos por la Red Nacional de Vigilancia Epidemiológica en el año 2015.
Enferm Infecc Microbiol Clin, 36 (2018), pp. 179-186
[7]
T. Rodrigo, J.M. García-García, J.A. Caminero, J. Ruiz-Manzano, L. Anibarro, M.M. García-Clemente, et al.
Evaluation of the integrated tuberculosis research program sponsored by the Spanish Society of Pulmonology and Thoracic Surgery: 11 years on.
Arch Bronconeumol, 56 (2020), pp. 483-492
[8]
World Health Organization (WHO).
Global Tuberculosis Report 2019. Geneva, Switzerland.
(2019),
[9]
World Health Organization (WHO).
Global Tuberculosis Report 2023. Geneva, Switzerland.
(2023),
[10]
M.E. Murphy, G.H. Wills, S. Murthy, C. Louw, A.L.C. Bateson, R.D. Hunt, et al.
Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study.
[11]
K.C. Horton, T. Sumner, M.G.J. Houben Rein, E.L. Corbett, R.G. White.
A Bayesian approach to understanding sex differences in tuberculosis disease burden.
Am J Epidemiol, 187 (2018), pp. 2431-2438
[12]
K.C. Horton, P. MacPherson, M.G.J. Houben Rein, R.G. White, E.L. Corbett.
Sex differences in tuberculosis burden and notifications in low- and middle-income countries: a systematic review and metanalysis.
PLOS Med, 13 (2016), pp. e1002119
[13]
I. Padberg, J. Bätzing-Feigenbaum, D. Sagebiel.
Association of extra-pulmonary tuberculosis with age, sex and season differs depending on the affected organ.
Int J Tuberc Lung Dis, 19 (2015), pp. 723-728
[14]
D. Dabitao, W.R. Bishai.
Sex and gender differences in tuberculosis pathogenesis and treatment outcomes.
[15]
T. Rodrigo, J.A. Gullón, E.M. Tabernero, L. Anibarro, J.P. Millet, A. Sáez, et al.
Impacto de la pandemia COVID-19 en el Programa Integrado de Investigación en Tuberculosis (PII-TB) de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR).
Enf Emerg, 21 (2022), pp. 81-84
[16]
M.L. Aznar, J. Espinosa-Pereiro, N. Saborit, N. Jové, F. Sánchez Martínez, S.M.L. Pérez-Recio, et al.
Impact of the COVID-19 pandemic on tuberculosis management in Spain.
Int J Infect Dis, 108 (2021), pp. 300-305
[17]
J. Nalunjogi, S. Mucching-Toscano, J.P. Sibomana, R. Centis, L. D’Ambrosio, J.W. Alffenaar, et al.
Impact of COVID-19 on diagnosis of tuberculosis, multidrug-resistant-tuberculosis, and on mortality in 11 countries in Europe, Northern America, and Australia. A Global Tuberculosis Network study.
Int J Infect Dis, 130 (2023), pp. S25-S29

A complete list of the Integrated Tuberculosis Research Programme Working Group members is provided in Appendix A.

Copyright © 2024. SEPAR
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?